Trump-Xi in Beijing — 5 trade scenarios over the next 6 months

On May 12, Trump arrived in Beijing and the Xi meeting is now on the docket. The agenda runs wider than trade — nuclear weapons, Taiwan, Iran, AI, critical minerals — but for cross-border companies, the line that matters is the November 10 Busan-truce countdown. 182 days left.

Set the table first. The October 2025 Busan agreement cut the US-side aggregate tariff on Chinese imports from 57% to 47% — the first material easing of the second Trump term. It simultaneously paused China's retaliatory tariffs and rare-earth export controls. Vice Premier He Lifeng held parallel working-level talks in Seoul with the US team on May 12–13 to pave the way for the Beijing summit.

From this set of facts on the table, five distinct paths run forward over the next six months — each with its own observable signal for when it crystallizes.

Scenario 1: Busan renewal plus add-ons, extended 18–24 months.

The most heavily supported path given the current desk-state. Trump publicly framed his expectation as "very good"; Xi confirmed the meeting structure. The October 2025 Busan rate cut of 57% → 47% is mature. The renewal version most likely adds a critical-minerals stable-supply framework on top — exactly the "critical minerals deal extension" CNBC's May 12 piece refers to.

If this path lands: 47% holds; the §301 16-economy investigation, when it lands at the July 24 target, likely narrows to a "China focus" with softened triggering — names retained, rates frozen. For CFOs: steel/aluminum, semiconductors, pharma, electronics medium-term sourcing frameworks continue under current configuration.

Signal to watch — frequency of vice-ministerial USTR-MOFCOM meetings over the next 30 days; whether the joint communiqué explicitly names rare-earth materials (neodymium, dysprosium, gallium, germanium, indium).

Scenario 2: G2 architecture — a deal larger than Busan.

Al Jazeera's May 12 piece floats this angle: a single larger framework covering trade + AI + nuclear + Taiwan agenda all in one stroke. For the trade line specifically, this would mean a phased tariff-reduction roadmap — say 47% stepping down to 25–30% across 2027–2028, with China opening AI chip imports and semiconductor equipment in exchange.

Probability is middling, difficulty is extreme. A full G2 framework is unrealistic in a single summit, but a leaders' joint statement could lay out direction with the 24-month working-group calendar locked in.

Signal to watch — page count of the joint statement. A 60+ page communiqué with cross-sector CEO witness ceremonies (autos, chips, rare earths) signals G2 architecture launch. A 3–5 page brief returns the read to Scenario 1.

Scenario 3: Partial renewal — talk by sector, land by sector.

Modeled on the 2020 Phase 1 pattern. Some categories see Busan extended — traditional steel/aluminum, textiles, chemicals — others negotiate on their own clocks. Semiconductors, critical minerals, AI-related categories most likely move to their own track, possibly ahead of or behind November 10.

This is the hardest scenario for CFO modeling: rates split by HS chapter, no more "US-China tariff" aggregate read. Apparel/furniture/toys stay at the 47% aggregate; semis/batteries/AI hardware on a separate track; steel/aluminum stay on §232 full-value; critical minerals on a new bilateral framework.

Signal to watch — whether USTR publishes a phased action document in mid-to-late July with sector-by-sector calendars.

Scenario 4: Talks collapse, Busan lapses — full pre-November 10 stack returns.

Low probability, but a scenario every CFO needs a playbook for. If Trump-Xi sessions stall on non-trade items (Iran, Taiwan), and November 10 arrives without a renewal — the Busan truce auto-expires.

Consequences are cold: full §232 / §301 / §122 stack returns to Chinese-origin goods. Chinese flat-rolled steel back to 90%+ aggregate. Patented pharma at 100%. AI chip export controls re-engage. China's countermeasures land under the April 7 Supply-Chain Security regulation framework — a single-source report (OQTIMA) that hasn't been fully verified, but if the regulation text exists as drafted, the trigger is pre-positioned.

Signal to watch — USTR's August decision-letter language; MOFCOM statements through People's Daily or the State Council Information Office. Either marker firing means activate the playbook.

Scenario 5: Non-trade decoupling — trade is "paused."

When Taiwan or Iran agenda collapses, the trade line is often technically frozen: no renewal, but no new escalation either, held in place "pending the next summit." This state is the hardest to plan against — you can't assume easing, you can't trigger contingency.

Signal to watch — whether the joint communiqué buries the trade section or omits it; whether the press briefing spends less than 5 minutes on trade questions. In this configuration, a September–October vice-ministerial meeting is likely the next probe.

Map the five paths onto one timeline —

July 1: USMCA trilateral review opens July 24: USTR's accelerated action target for the §301 16-economy investigation July 31: §232 pharma 100% rate takes effect for the 17 Annex III companies September 29: §232 pharma rate extends to other pharma companies November 10: Busan agreement expiry date

Scenarios 1 and 2 will be decided around July 24 — how USTR handles the 16-economy investigation that day is the first market signal on whether the Busan posture is renewable. Scenarios 3 and 4 are decided in late September through early October. Scenario 5 implies another vice-ministerial round in September, pushing the matter into 2027.

The trade line isn't isolated — nuclear, Taiwan, or Iran going sideways resets the trade arc with it. Three to five days in Beijing this week sets the starting position for every possibility over the next six months.